Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Stock Quote

NASDAQTROV
$1.72
NASDAQTROV
Open
$1.77
Change
-$0.01 (-0.58%)
Day's Range
$1.70 - $1.79
52-Week Range
$0.88 - $9.65
Volume
79.6K
Market Cap
$12.9M